$165 Million is the total value of Birchview Capital, LP's 165457 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 87.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMY | Buy | BRISTOL-MYERS SQUIBB CO | $46,592,000 | +6.4% | 792,386 | +0.8% | 28.16% | -27.5% |
| AWH | New | ASPIRA WOMEN'S HEALTH INC | $12,661,000 | – | 3,297,247 | +100.0% | 7.65% | – |
| QDEL | Buy | QUIDEL CORP | $11,398,000 | +138.6% | 50,944 | +4.3% | 6.89% | +62.6% |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $9,516,000 | +48.6% | 78,000 | +5.4% | 5.75% | +1.2% |
| ACAD | Buy | ACADIA PHARMACEUTICALS INC | $4,508,000 | +16.0% | 93,000 | +1.1% | 2.72% | -21.0% |
| BLUE | New | BLUEBIRD BIO INC | $3,662,000 | – | 60,000 | +100.0% | 2.21% | – |
| KPTI | Buy | KARYOPHARM THERAPEUTICS INC | $3,182,000 | +11.9% | 168,000 | +13.5% | 1.92% | -23.8% |
| SLNO | Buy | SOLENO THERAPEUTICS INC | $1,836,000 | +282.5% | 826,899 | +310.4% | 1.11% | +160.6% |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $1,799,000 | +149.9% | 260,000 | +44.4% | 1.09% | +70.1% |
| EPZM | Buy | EPIZYME INC | $1,124,000 | +20.7% | 70,000 | +16.7% | 0.68% | -17.8% |
| ETRN | New | EQUITRANS MIDSTREAM CORPORATIO | $1,106,000 | – | 133,050 | +100.0% | 0.67% | – |
| MYOK | New | MYOKARDIA INC | $966,000 | – | 10,000 | +100.0% | 0.58% | – |
| CLR | New | CONTINENTAL RESOURCES INC | $677,000 | – | 38,600 | +100.0% | 0.41% | – |
| NARI | New | INARI MEDICAL INC | $484,000 | – | 10,000 | +100.0% | 0.29% | – |
| OVV | New | OVINTIV INC | $328,000 | – | 34,350 | +100.0% | 0.20% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2020-09-25
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACCELERATE DIAGNOSTICS INC | 36 | Q3 2023 | 34.6% |
| QUIDELORTHO CORP | 36 | Q3 2023 | 8.6% |
| MASIMO CORP | 36 | Q3 2023 | 2.2% |
| PIONEER NATURAL RESOURCES CO (PXD) | 36 | Q3 2023 | 0.7% |
| XENCOR INC | 35 | Q3 2023 | 0.4% |
| NEUROCRINE BIOSCIENCES INC | 33 | Q3 2023 | 7.4% |
| CORCEPT THERAPEUTICS INC | 32 | Q3 2023 | 1.2% |
| BIOGEN INC | 31 | Q2 2022 | 3.1% |
| CONTRAFECT CORP | 30 | Q3 2022 | 1.6% |
| YIELD10 BIOSCIENCE INC | 26 | Q3 2023 | 0.6% |
View Birchview Capital, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SOLENO THERAPEUTICS INC | March 19, 2019 | 742,635 | 2.3% |
| YIELD10 BIOSCIENCE, INC. | December 29, 2017 | 186,079 | 2.2% |
| HANSEN MEDICAL INC | February 16, 2016 | ? | ? |
| METABOLIX, INC. | June 23, 2015 | 749,696 | 2.8% |
View Birchview Capital, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3/A | 2024-02-20 |
| 4/A | 2024-02-20 |
| SC 13G/A | 2024-02-20 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-04-07 |
| 4 | 2023-03-27 |
| 3 | 2023-02-13 |
View Birchview Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.